Price T Rowe Associates Inc Y M Abs Therapeutics, Inc. Transaction History
Price T Rowe Associates Inc
- $867 Billion
- Q4 2024
A detailed history of Price T Rowe Associates Inc transactions in Y M Abs Therapeutics, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 14,067 shares of YMAB stock, worth $87,778. This represents 0.0% of its overall portfolio holdings.
Number of Shares
14,067
Previous 22,537
37.58%
Holding current value
$87,778
Previous $297,000
62.63%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding YMAB
# of Institutions
112Shares Held
27.1MCall Options Held
40.3KPut Options Held
400-
Paradigm Biocapital Advisors LP New York, NY4.24MShares$26.4 Million1.27% of portfolio
-
Black Rock Inc. New York, NY2.94MShares$18.3 Million0.0% of portfolio
-
Acorn Capital Advisors, LLC New York, NY2.86MShares$17.9 Million12.11% of portfolio
-
Sofinnova Investments, Inc. Menlo Park, CA2.19MShares$13.7 Million1.4% of portfolio
-
Vanguard Group Inc Valley Forge, PA2MShares$12.5 Million0.0% of portfolio
About Y-mAbs Therapeutics, Inc.
- Ticker YMAB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,719,500
- Market Cap $273M
- Description
- Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment o...